Literature DB >> 2521660

In vitro manipulation of human anti-DNA antibody production by anti-idiotypic antibodies conjugated with neocarzinostatin.

T Sasaki1, E Tamate, T Muryoi, O Takai, K Yoshinaga.   

Abstract

Anti-DNA Id, 0-81, consist of 5 to 51% of Id in human anti-ssDNA antibodies; NE-1-Id shares 2 to 20% of those in anti-dsDNA antibodies. Thus, both 0-81-Id and NE-1-Id are of the cross-reactive Id that are commonly present among anti-DNA antibodies. In order to manipulate the production of anti-DNA antibodies by human PBL, we used mouse antiidiotypic mAb or those conjugated with a cytotoxic agent, neocarzinostatin. Treatment with the conjugates caused profound suppression of anti-ssDNA and anti-dsDNA antibody synthesis related to 0-81- and NE-1-Id. This was attributed to the specific killing of the clones bearing anti-DNA Id among the lymphocytes, evidenced by the indirect rosette formation tests. The Id-mediated suppression was not solely due to selective elimination of Id-positive B cells, because 50 to 92% of anti-DNA antibodies were suppressed by treatment with the conjugates. This was supported by flow cytometry analysis that showed a decrease of anti-Id-reactive cells when T cells were treated with the conjugates. This method, then, will permit an analysis of the question as to whether T cells reactive to anti-idiotypic antibodies might participate in the regulatory mechanism for anti-DNA production and, in addition, may lead to a new therapy for SLE.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2521660

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  Incidence of anti-DNA idiotype-positive cells in human peripheral blood.

Authors:  O Takai; T Sasaki; T Muryoi; N Harata; H Hashimoto; K Yoshinaga
Journal:  J Clin Immunol       Date:  1989-07       Impact factor: 8.317

2.  Therapeutic treatment of New Zealand mouse disease by a limited number of anti-idiotypic antibodies conjugated with neocarzinostatin.

Authors:  N Harata; T Sasaki; H Osaki; T Saito; S Shibata; T Muryoi; O Takai; K Yoshinaga
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

3.  Suppression of experimental systemic lupus erythematosus (SLE) with specific anti-idiotypic antibody-saporin conjugate.

Authors:  M Blank; J Manosroi; Y Tomer; A Manosroi; J Kopolovic; S Charcon-Polak; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  1994-12       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.